Compare AVLN & SBET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | SBET |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2026 | 2025 |
| Metric | AVLN | SBET |
|---|---|---|
| Price | $27.52 | $9.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $62.25 | $16.63 |
| AVG Volume (30 Days) | 192.8K | ★ 7.5M |
| Earning Date | 08-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $28,055,000.00 |
| Revenue This Year | N/A | $62.83 |
| Revenue Next Year | N/A | $74.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 666.04 |
| 52 Week Low | $24.90 | $4.46 |
| 52 Week High | $40.17 | $19.53 |
| Indicator | AVLN | SBET |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 58.27 |
| Support Level | $25.86 | $8.69 |
| Resistance Level | $30.45 | $10.44 |
| Average True Range (ATR) | 2.25 | 0.51 |
| MACD | -0.56 | -0.06 |
| Stochastic Oscillator | 14.12 | 65.38 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Sharplink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.